Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ligufalimab + Azacitidine in Higher-Risk MDS
NCT04900350Phase 2Active, not recruiting
- Sponsor
- Akeso, Inc.
- Start
- Jun 2021
- Primary completion
- Sep 2025
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of ligufalimab in myelodysplastic syndrome (MDS), sponsored by Akeso, Inc.. Started Jun 2021; status: active, not recruiting.
02
Drugs
ligufalimab
03
Conditions
myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on NCT04900350.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04900350.